Glorimet PG 2 Tablet is a combination oral hypoglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This formulation harnesses the complementary mechanisms of its active ingredients to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake by tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, including insulin resistance and impaired insulin secretion. Glorimet PG 2 Tablet is typically prescribed when monotherapy or dual therapy is insufficient to achieve glycemic targets. It should be used alongside lifestyle modifications such as diet and exercise. Caution is advised in patients with hepatic, renal, or cardiac impairment, and monitoring for potential adverse effects like hypoglycemia, lactic acidosis, and fluid retention is essential. This combination therapy offers a comprehensive approach to improving glycemic control in patients with type 2 diabetes mellitus.